Skip to main content
OpenTrials
Completed

NCT Number: NCT05104450

Pragmatic Obstructive Sleep Apnea Weight Loss Trial Assessing Effectiveness and Reach

Prevalent obesity related conditions like obstructive sleep apnea (OSA) represent an important opportunity to improve population health. OSA reduces quality of life and is associated with greater risk for cardiovascular disease. Although obesity is the single greatest reversible risk factor for OSA, patients with OSA and obesity rarely receive weight loss care to reverse OSA and other serious comorbidities. Efficacy trials reinforce that time and resource intensive lifestyle-based weight loss programs improve weight and physiologic measures of OSA severity (apnea hypopnea index, AHI). However, there are barriers to translating these findings into meaningful gains for population health. To meet these challenges, the investigators propose a pragmatic trial of proactively offering a remote video-based and self-directed lifestyle-based weight loss intervention with remote coaching to patients with OSA. The investigators primary aim is to test the effectiveness of a proactively delivered and pragmatic lifestyle intervention to improve co-primary endpoints of sleep-related quality of life and weight among patients with OSA and obesity. Secondarily, the investigators will compare additional outcomes between groups including cardiovascular risk scores, sleep symptoms, AHI, well-being, and global ratings of change. Finally, the investigators will also conduct an implementation process evaluation informed by the RE-AIM framework to identify barriers and facilitators to widespread implementation.

The investigators will identify patients with OSA and obesity nationwide (n=696) in VA using data from the VA's Corporate Data Warehouse (CDW), and the investigators will contact potentially eligible patients. After confirming eligibility and consent, the investigators will randomly assign subjects to receive the study's lifestyle intervention or usual care alone. The study uses CDW to assess weight change. Subjects will complete questionnaires at baseline at 3, 12 and 21 months after randomization. The lifestyle intervention in POWER focuses on gradual lifestyle behavior change aimed at improving eating habits and increasing physical activity. It encourages participants to gradually achieve and maintain a 5-10% loss of baseline body weight and at least 150 minutes of moderate-intensity physical activity, such as brisk walking, each week. The lifestyle intervention program consists of watching one video, completing corresponding written self-guided learning materials, and tracking food intake and physical activity each week for the first 12 weeks, then working through 10 additional written handouts and continued food and activity tracking for the next nine months. Intervention participants will have access to a lifestyle coach as desired for the full 12-month intervention period.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Obesity Apnea Behavior Body Weight Body Weight Changes Dyssomnias Motor Activity Nervous System Diseases Nutrition Disorders Nutritional and Metabolic Diseases Overnutrition Overweight Pathological Conditions, Signs and Symptoms Respiration Disorders Respiratory Tract Diseases Signs and Symptoms Sleep Apnea Syndromes Sleep Apnea, Obstructive Sleep Disorders, Intrinsic Sleep Wake Disorders Weight Loss

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

VA Puget Sound Health Care System Seattle Division, Seattle, WA

Seattle, Washington, 98108-1532, United States

About this study

  • Objective(s) and Hypotheses:

The investigators' primary aim is to test the effectiveness of a proactively delivered and pragmatic weight loss intervention to improve co-primary endpoints of sleep-related quality of life and weight among Veterans with obstructive sleep apnea (OSA) and obesity.

Secondarily, the investigators will compare additional outcomes between groups including cardiovascular risk scores, sleep symptoms, AHI, well-being, and global ratings of change. The investigators will also conduct an implementation process evaluation informed by the RE-AIM framework to identify predictors and determinants of population uptake of the intervention.

  • Research Design:

The investigators plan a hybrid type 1 pragmatic randomized controlled trial assessing effectiveness and an implementation process evaluation.

  • Methodology The investigators will proactively identify patients with OSA and obesity nationwide in VA using data from the CDW (n=696), randomizing patients 1:1 to usual care plus the lifestyle-based weight loss intervention or usual care alone. The investigators will collect primary outcomes at 12 months, but will also collect outcomes at 3 and up to 21 months to assess trends over time.
  • Findings/Progress to Date:

Recruitment and outcome collection completed, analysis is ongoing and not yet complete.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of obstructive sleep apnea (OSA) on sleep study (sleep provider confirmed)
  • Recent body mass index between 30.0-44.9 kg/m2 and at least one additional plausible BMI in last 12 months
  • Access to DVD player, computer, and/or internet
  • Able to participate fully in all study protocol/procedures including informed consent

Exclusion criteria

  • Inability to speak, read, or understand English
  • Recent or active weight loss interventions including use of prescription weight-loss medications, participation in group or individual weight loss programs provided by trained personnel, and prior bariatric surgery or plans for bariatric surgery during the study period.
  • Expected weight loss because of alternate explanations such as from illness
  • High variability in weight due to fluctuations in volume status (e.g. ascites - liver disease, chronic heart failure)
  • Safety and/or adherence concerns due to severe physical or mental health issues, or life expectancy <24 months
  • Pregnant, lactating, or planning to become pregnant during the study period
  • Participation in other intervention studies

Treatment and study plan

Lifestyle Intervention

Behavioral

Intervention Arm: Usual Care plus a lifestyle behavior change intervention aimed at improving eating habits and increasing physical activity. The lifestyle behavior change intervention encourages participants to gradually achieve and maintain a 5-10% loss of baseline body weight and at least 150 minutes of moderate-intensity physical activity, such as brisk walking, each week. The lifestyle intervention program consists of watching one video, completing corresponding written self-guided learning materials, and tracking food intake and physical activity each week for the first 12 weeks, then working through 10 additional written handouts and continued food and activity tracking for the next nine months. Intervention participants will have access to a lifestyle coach as desired for the full 12-month intervention period.

Primary outcomes

  1. Change in Sleep-related Quality of Life

    Time frame: baseline to 12 months post randomization

    The investigators will compare change in Functional Outcomes of Sleep questionnaire (FOSQ) score between groups.

    The minimum value of FOSQ is 5, the maximum is 20, and a higher value indicates a better outcome.

  2. Change in Weight

    Time frame: baseline to between 9 and 15 months post randomization

    The investigators will compare change in weights between intervention and control using clinic weights from VA medical record

Secondary outcomes

  1. Cardiovascular Risk Scores

    Time frame: baseline to 12 months post randomization

    The investigators will compare change in cardiovascular risk scores between intervention and control using the non-laboratory Framingham algorithm. The minimum value in this risk score is 1, the maximum is 30%, and a higher value indicates greater risk of cardiovascular disease (worse outcome).

  2. PROMIS - Sleep Disturbance Survey Change

    Time frame: baseline to 3 months post randomization

    The investigators will compare change in sleep disturbance between intervention and control using the Patient Reported Outcomes Measurement Information System (PROMIS) - Sleep Disturbance Survey. Individuals' responses are used to generate a T-score, corresponding to a population mean of 50 with standard deviation of 10. The minimum value for PROMIS Sleep Disturbance is a T-score of 28.9, the maximum is a T-score of 76.5, and a greater value indicates greater sleep disturbance (worse outcome).

  3. PROMIS - Sleep Related Impairment Survey Change

    Time frame: baseline to 3 months post randomization

    The investigators will compare change in sleep-related impairment between intervention and control using the Patient Reported Outcomes Measurement Information System (PROMIS) -Sleep Related Impairment Survey. Individuals' responses are used to generate a T-score, corresponding to a population mean of 50 with standard deviation of 10. The minimum value for PROMIS Sleep Related Impairment is a T-score of 30.0, the maximum is a T-score of 80.1, and a greater value indicates greater sleep related impairment (worse outcome).

  4. Systolic Blood Pressure From VA Medical Record

    Time frame: baseline to 12 months post randomization

    The investigators will compare change in systolic blood pressure values between intervention and control.

  5. Treatment Usage Per Day

    Time frame: baseline to 3 months post randomization

    The investigators will compare change in daily OSA treatment usage between groups using self-report.

  6. Apnea Hypopnea Index 1b Criteria

    Time frame: 12 months post randomization

    The investigators will conduct home sleep apnea tests among a subset of patients in each group to compare apnea hypopnea index (a physiologic measure of OSA severity) between groups at 12 months. The apnea hypopnea index measures the number of times per hour of sleep in which an individual stops breathing (apnea) or nearly stops breathing (hypopnea). For this outcome, we will measure apneas and hypopneas using the 1B criteria of the American Academy of Sleep Medicine.

  7. Longer-term Change in Weight

    Time frame: baseline to between 18 and 24 months post randomization

    The investigators will compare longer-term change in weight between intervention and control using clinic weights from VA medical record

  8. Short-term Change in Sleep-related Quality of Life

    Time frame: baseline to 3 months post randomization

    The investigators will compare short-term change in Functional Outcomes of Sleep questionnaire (FOSQ) between groups. The minimum value of FOSQ is 5, the maximum is 20, and a higher value indicates a better outcome.

  9. Longer-term Change in Sleep-related Quality of Life

    Time frame: baseline to 21 months post randomization

    The investigators will compare longer-term change in Functional Outcomes of Sleep questionnaire (FOSQ) between groups. The minimum value of FOSQ is 5, the maximum is 20, and a higher value indicates a better outcome.

  10. Global Rating of Change

    Time frame: 3 months post randomization

    The investigators will compare perceived change in symptoms between groups using the single-item patients' global impression of change (PGI-C). PGI-C has been validated in the context of OSA treatment and asks patients to rate symptom changes on a 7 point scale from "1-Very Much Improved" to "7-Very Much Worse".

  11. Change in Self-reported Well-being

    Time frame: baseline to 3 months post randomization

    The investigators will compare change in self-reported well-being between groups. Participants will complete a 3-item Well-being signs (WBS) survey asking them to rate the proportion of time they are satisfied, involved, and functioning their best in activities that they value. The minimum value is 0% and the maximum value is 100%, and a higher value on WBS indicates a better outcome.

  12. Cardiovascular Risk Scores

    Time frame: baseline to 21 months post randomization

    The investigators will compare cardiovascular risk scores between intervention and control using the non-laboratory Framingham algorithm. The minimum value in this risk score is 1, the maximum is 30%, and a higher value indicates greater risk of cardiovascular disease (worse outcome).

  13. PROMIS - Sleep Disturbance Survey Change

    Time frame: baseline to 12 months post randomization

    The investigators will compare sleep-related disturbance between intervention and control using the Patient Reported Outcomes Measurement Information System (PROMIS) - Sleep Disturbance Survey.

    Individuals' responses are used to generate a T-score, corresponding to a population mean of 50 with standard deviation of 10. The minimum value for PROMIS Sleep Disturbance is a T-score of 28.9, the maximum is a T-score of 76.5, and a greater value indicates greater sleep disturbance (worse outcome).

  14. PROMIS - Sleep Disturbance Survey Change

    Time frame: baseline to 21 months post randomization

    The investigators will compare sleep-related disturbance between intervention and control using the Patient Reported Outcomes Measurement Information System (PROMIS) - Sleep Disturbance Survey.

    Individuals' responses are used to generate a T-score, corresponding to a population mean of 50 with standard deviation of 10. The minimum value for PROMIS Sleep Disturbance is a T-score of 28.9, the maximum is a T-score of 76.5, and a greater value indicates greater sleep disturbance (worse outcome).

  15. PROMIS - Sleep Related Impairment Survey Change

    Time frame: baseline to 12 months post randomization

    The investigators will compare sleep-related impairment between intervention and control using the Patient Reported Outcomes Measurement Information System (PROMIS) -Sleep Related Impairment Survey. Individuals' responses are used to generate a T-score, corresponding to a population mean of 50 with standard deviation of 10. The minimum value for PROMIS Sleep Related Impairment is a T-score of 30.0, the maximum is a T-score of 80.1, and a greater value indicates greater sleep related impairment (worse outcome).

  16. PROMIS - Sleep Related Impairment Survey Change

    Time frame: baseline to 21 months post randomization

    The investigators will compare sleep-related impairment between intervention and control using the Patient Reported Outcomes Measurement Information System (PROMIS) -Sleep Related Impairment Survey. Individuals' responses are used to generate a T-score, corresponding to a population mean of 50 with standard deviation of 10. The minimum value for PROMIS Sleep Related Impairment is a T-score of 30.0, the maximum is a T-score of 80.1, and a greater value indicates greater sleep related impairment (worse outcome).

  17. Systolic Blood Pressure From VA Medical Record

    Time frame: baseline to 21 months post randomization

    The investigators will compare change in systolic blood pressure values between intervention and control.

  18. Diastolic Blood Pressure From VA Medical Record

    Time frame: baseline to 12 months post randomization

    The investigators will compare change in diastolic blood pressure values between intervention and control.

  19. Diastolic Blood Pressure From VA Medical Record

    Time frame: baseline to 21 months post randomization

    The investigators will compare change in diastolic blood pressure values between intervention and control.

  20. Treatment Usage Per Day

    Time frame: baseline to 12 months post randomization

    The investigators will compare change in daily OSA treatment usage between groups using self-report.

  21. Treatment Usage Per Day

    Time frame: baseline to 21 months post randomization

    The investigators will compare change in daily OSA treatment usage between groups using self-report.

  22. Global Rating of Change

    Time frame: 12 months post randomization

    The investigators will compare perceived change in symptoms between groups using the single-item patients' global impression of change (PGI-C). PGI-C has been validated in the context of OSA treatment and asks patients to rate symptom changes on a 7 point scale from "1-Very Much Improved" to "7-Very Much Worse".

  23. Global Rating of Change

    Time frame: 21 months post randomization

    The investigators will compare perceived change in symptoms between groups using the single-item patients' global impression of change (PGI-C). PGI-C has been validated in the context of OSA treatment and asks patients to rate symptom changes on a 7 point scale from "1-Very Much Improved" to "7-Very Much Worse".

  24. Change in Self-reported Well-being

    Time frame: baseline to 12 months post randomization

    The investigators will compare change in self-reported well-being between groups. Participants will complete a 3-item Well-being signs (WBS) survey asking them to rate the proportion of time they are satisfied, involved, and functioning their best in activities that they value. The minimum value is 0% and the maximum value is 100%, and a higher value on WBS indicates a better outcome.

  25. Change in Self-reported Well-being

    Time frame: baseline to 21 months post randomization

    The investigators will compare change in self-reported well-being between groups. Participants will complete a 3-item Well-being signs (WBS) survey asking them to rate the proportion of time they are satisfied, involved, and functioning their best in activities that they value. The minimum value is 0% and the maximum value is 100%, and a higher value on WBS indicates a better outcome.

  26. Apnea Hypopnea Index 1a Criteria

    Time frame: 12 months post randomization

    The investigators will conduct home sleep apnea tests among a subset of patients in each group to compare apnea hypopnea index (a physiologic measure of OSA severity) between groups at 12 months. The apnea hypopnea index measures the number of times per hour of sleep in which an individual stops breathing (apnea) or nearly stops breathing (hypopnea). For this outcome, we will measure apneas and hypopneas using the 1A criteria of the American Academy of Sleep Medicine.

Sponsors and collaborators

Lead sponsor

VA Office of Research and Development

Fed

Registry information

Official study title

Pragmatic Obstructive Sleep Apnea Weight Loss Trial Assessing Effectiveness and Reach (POWER)

Acronym: POWER

Important dates

Study start
2022
Primary completion
2024
Study completion
2025
First posted
Nov 3, 2021
Registry last updated
Jun 12, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.